Concurrent Chemoradiotherapy with Weekly Paclitaxel for Locally Advanced Non-small Cell Lung Cancer
Journal of Lung Cancer 2009³â 8±Ç 1È£ p.8 ~ p.12
Á¤¼ºÇö(Jeong Seong-Hyun) - ¾ÆÁÖ´ëÇб³ ÀÇ°ú´ëÇÐ Á¾¾çÇ÷¾×³»°úÇб³½Ç
Á¤ÀçÈ£(Jung Jae-Ho) - ¾ÆÁÖ´ëÇб³ ÀÇ°ú´ëÇÐ Á¾¾çÇ÷¾×³»°úÇб³½Ç
ÀÌÇö¿ì(Lee Hyun-Woo) - ¾ÆÁÖ´ëÇб³ ÀÇ°ú´ëÇÐ Á¾¾çÇ÷¾×³»°úÇб³½Ç
°¼®À±(Kang Seok-Yun) - ¾ÆÁÖ´ëÇб³ ÀÇ°ú´ëÇÐ Á¾¾çÇ÷¾×³»°úÇб³½Ç
¾È¹Ì¼±(Ahn Mi-Sun) - ¾ÆÁÖ´ëÇб³ ÀÇ°ú´ëÇÐ Á¾¾çÇ÷¾×³»°úÇб³½Ç
ÃÖ¿ë¿ø(Choi Yong-Won) - ¾ÆÁÖ´ëÇб³º´¿ø ¾Ï¼¾ÅÍ
ȲÀ±È£(Hwang Yoon-Ho) - ¾ÆÁÖ´ëÇб³ ÀÇ°ú´ëÇÐ Á¾¾çÇ÷¾×³»°úÇб³½Ç
¿À¿µÅÃ(Oh Young-Taek) - ¾ÆÁÖ´ëÇб³ ÀÇ°ú´ëÇÐ ¹æ»ç¼±Á¾¾çÇб³½Ç
ÃÖÁøÇõ(Choi Jin-Hyuk) - ¾ÆÁÖ´ëÇб³ ÀÇ°ú´ëÇÐ Á¾¾çÇ÷¾×³»°úÇб³½Ç
½Å½Â¼ö(Shin Seung-Soo) - ¾ÆÁÖ´ëÇб³ ÀÇ°ú´ëÇРȣÈí±â³»°úÇб³½Ç
¹Ú±¤ÁÖ(Park Kwang-Joo) - ¾ÆÁÖ´ëÇб³ ÀÇ°ú´ëÇРȣÈí±â³»°úÇб³½Ç
Abstract
Purpose: Concurrent chemoradiotherapy (CCRT) is the standard treatment for locally advanced non-small cell lung cancer (NSCLC). Paclitaxel is an active agent against NSCLC and it has a radiosensitizing effect. We investigated the efficacy and toxicity of weekly paclitaxel administration along with concurrent radiotherapy for treating locally advanced and locally recurrent NSCLC.
Materials and Methods: Twenty-five previously untreated stage III or locally recurrent NSCLC patients received weekly paclitaxel (60 mg/m2) and concurrent radiotherapy. Chemotherapy was given on days 1, 8, 15 and 22. Concurrent radiotherapy at 1.5 Gy was given twice a day to a total dose of 54 Gy in 3.5 weeks. After the completion of CCRT, consolidation chemotherapy was delivered if possible.
Results: The overall response rate was 72% with one complete response and 17 partial responses. The median overall survival was 16 months with a 2 year survival rate and a 5 year survival rate of 38% and 24%, respectively. The rate of grade ¡Ã3 radiation pneumonitis was 16% (4 patients) and 2 patients were died from the pneumonitis. The rate of grade 3 radiation esophagitis was 12% (3 patients) and the hematologic toxicities were not significant.
Conclusion: Weekly paclitaxel with concurrent radiotherapy is effective for treating locally advanced and locally recurrent NSCLC, but radiation pneumonitis is the major toxicity and this is potentially fatal.
Å°¿öµå
Non-small cell lung carcinoma, Concurrent chemoradiotherapy, Paclitaxel
KMID :
0982820090080010008
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
À¯È¿¼º°á°ú(Recomendation)
Weekly paclitaxel with concurrent radiotherapy is effective for treating locally advanced and locally recurrent NSCLC, but radiation pneumonitis is the major toxicity and this is potentially fatal.